JNLF 2026: The Evolution of Migraine Management

The 2026 Journées Nationales de Neurologie (JNLF) has highlighted a significant shift in the clinical approach to migraine management, moving away from broad-spectrum preventive medications toward therapies that target the specific biological pathways of the disease. This evolution in care focuses on the integration of targeted molecular treatments to reduce the frequency and severity of attacks while minimizing the systemic side effects associated with older pharmacological options.

For decades, migraine prevention relied heavily on medications originally developed for other conditions, such as beta-blockers for hypertension, anticonvulsants for epilepsy, or antidepressants. While effective for some, these treatments often caused significant side effects that led to low patient adherence. The current evolution in neurology, as discussed during the JNLF 2026 sessions, emphasizes the use of agents specifically designed for the pathophysiology of migraine.

The Role of CGRP Pathway Inhibition

At the center of this therapeutic evolution is the Calcitonin Gene-Related Peptide (CGRP) pathway. CGRP is a neuropeptide that acts as a potent vasodilator and is heavily involved in the transmission of pain during a migraine attack. By blocking the production, release, or reception of CGRP, clinicians can interrupt the cascade of neurogenic inflammation that characterizes the migraine experience.

Two primary classes of CGRP-targeted therapies have emerged as the pillars of modern migraine management: monoclonal antibodies and gepants.

Monoclonal antibodies are large-molecule proteins administered typically via injection. They are designed for long-term prevention by binding either to the CGRP ligand itself or to its receptor, effectively neutralizing the peptide’s impact over several weeks or months.

In contrast, gepants are small-molecule CGRP receptor antagonists. Unlike monoclonal antibodies, gepants can be administered orally and are used for both the acute treatment of an active migraine and, in some cases, for prevention. This versatility allows neurologists to tailor the treatment to the patient’s specific attack pattern.

Personalizing Migraine Treatment

The evolution of migraine care described at JNLF 2026 is not only about new drugs but also about the precision with which they are applied. Neurologists are increasingly utilizing a stratified approach to treatment, where the choice of therapy is dictated by the patient’s migraine phenotype, comorbidities, and previous response to medication.

This personalized approach involves several key considerations:

• Attack Frequency: Patients with chronic migraine, defined as 15 or more headache days per month, are more likely to be candidates for monoclonal antibody prevention.
• Tolerability: For patients who cannot tolerate the cardiovascular or metabolic side effects of older preventives, CGRP inhibitors offer a more targeted alternative.
• Acute Needs: For those who experience severe nausea or have contraindications to triptans, such as certain cardiovascular risks, gepants provide a safer acute intervention.

The transition toward these targeted therapies represents a shift in the goal of treatment. Rather than simply suppressing symptoms, the objective is now to stabilize the neurological environment to prevent the onset of the migraine cascade entirely.

Remaining Challenges and Clinical Outlook

Despite the progress in pharmacological options, several challenges remain in the widespread implementation of these advanced protocols. Access to CGRP-targeted therapies can vary based on insurance coverage and healthcare system regulations, which may limit the ability of all patients to transition from older, less specific medications.

clinicians continue to monitor the long-term effects of CGRP inhibition. Because CGRP plays a role in protecting blood vessels during certain types of cardiovascular stress, ongoing research is focused on ensuring that long-term blockade of this pathway does not increase risks for patients with pre-existing vascular conditions.

The discussions at JNLF 2026 suggest that the next phase of evolution will likely involve the integration of digital health tools. The use of electronic diaries and wearable sensors to track triggers and response patterns in real-time is expected to further refine the timing and dosage of these targeted therapies, moving migraine management closer to a truly individualized medical model.